Takeda Pharmaceutical Company Limited vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends

Comparing SG&A expenses of Takeda and Apellis over a decade.

__timestampApellis Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20142908166612613000000
Thursday, January 1, 20156356782650773000000
Friday, January 1, 20164303743619061000000
Sunday, January 1, 201710463151628106000000
Monday, January 1, 201822639184717599000000
Tuesday, January 1, 201967046483964737000000
Wednesday, January 1, 2020139401000875663000000
Friday, January 1, 2021176771000886361000000
Saturday, January 1, 2022277163000997309000000
Sunday, January 1, 20235008150001053819000000
Monday, January 1, 20241053819000000
Loading chart...

Unleashing the power of data

SG&A Expense Trends: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Apellis Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Takeda's SG&A expenses have shown a steady increase, peaking at approximately 1.05 trillion yen in 2023, reflecting a strategic expansion and investment in global markets. In contrast, Apellis Pharmaceuticals, a relatively smaller player, has seen its SG&A expenses grow from a modest 2.9 million dollars in 2014 to a significant 500 million dollars in 2023, marking a staggering increase of over 17,000%. This dramatic rise underscores Apellis's aggressive market penetration and scaling efforts. While Takeda's expenses dwarf those of Apellis, the latter's rapid growth trajectory is noteworthy, highlighting its potential to disrupt the market.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025